Why the study?
Does telmisartan increase the incidence of cancer compared with other ARBs in patients newly treated with ARBs?
Population
62,109 patients newly treated with angiotensin receptor blockers between 2000 and 2008 from the United…
Comparison
Telmisartan (n=3,438) vs Other angiotensin receptor blockers
Design
Cohort
Follow-up
followed until December 2010
Authors
Loading...
Telmisartan shows no excess cancer risk versus other ARBs in UK primary care; leaves open need for confirmatory randomized data.
Does telmisartan increase the incidence of cancer compared with other ARBs in patients newly treated with ARBs?
In a large UK cohort, telmisartan was not associated with an increased risk of cancer compared to other ARBs, providing reassurance regarding its short-term safety.
Taşçılar et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: